A large study, led by the World Health Organization (WHO), suggests that the antiviral drug Remdesivir did not help hospitalised Covid-19 patients, in contrast to an earlier study that made the medicine a standard of care in the United States and many other countries.
The results announced on Friday do not negate the previous ones, and the WHO study was not as rigorous as the earlier one led by the U.S. National Institutes of Health. But they add to concerns about how much value the pricey drug gives because none of the studies have found it can improve survival.
The drug has not been approved for Covid-19 in the U.S., but it was authorised for emergency use after the previous study found it shortened recovery time by five days on average. It is approved for use against Covid-19 in the United Kingdom and Europe, and is among the treatments U.S. President Donald Trump received when he was infected earlier this month.
Bangladesh coronavirus situation
The health authorities reported 1,527 new cases of Covid-19, bringing the total caseload to 386,086 as of Friday.
During this period, 15 coronavirus deaths were recorded, pushing the death tally to 5,623.
The fatality rate in Bangladesh is 1.46 percent, the Directorate General of Health Services (DGHS) said.
So far, 2,140,129 samples have been tested and 18.04 percent of them have turned out to be positive.
Currently, there are 79,725 active cases in the country.